key: cord-0976081-3p2xcuq7 authors: Pergolizzi, Joseph; LeQuang, Jo Ann; Umeda‐Raffa, Sumiyo; Fleischer, Charles; Pergolizzi, Joseph; Pergolizzi, Claudio; Raffa, Robert B. title: The Zika virus: Lurking behind the COVID‐19 pandemic? date: 2020-11-20 journal: J Clin Pharm Ther DOI: 10.1111/jcpt.13310 sha: 4aa49a58ef67e4c2fdd5abc7a3e9594ac1256506 doc_id: 976081 cord_uid: 3p2xcuq7 WHAT IS KNOWN AND OBJECTIVE: The sudden and extensive outbreak of coronavirus (SARS‐CoV‐2) has overshadowed another developing viral threat: the Zika flavivirus. Of particular concern is that pregnant women can pass Zika virus to the foetus, and there is a strong implication of an association between Zika virus infection and foetal microcephaly. Currently, there is no vaccine, and there is no cure. METHODS: Published literature and Internet sources were searched for information related to Zika virus, its transmission, its clinical presentation and sequalae, prevention and implications (practice and regulatory) for healthcare providers. The identified English sources were reviewed, assessed and synthesized. Emphasis was placed on providing an overview of the problem, and identification of unmet needs and future directions. RESULTS AND DISCUSSION: Zika virus poses a major challenge for healthcare providers, particularly in areas unaccustomed to it, since it is transmitted to humans by the vector Aedes aegypti mosquito. The outbreak impacts every healthcare provider, because every provider is required to report cases of Zika infection to their state or local health agencies––whether the infection is confirmed or merely suspected. Since the virus has become a worldwide crisis, healthcare providers will need to work across national boundaries and medical disciplines in order to educate patients about Zika symptoms and the mosquito vector. Until further information is known, infected patients (male and female) are being advised to avoid conceiving a child. WHAT IS NEW AND CONCLUSION: Until a vaccine is developed or effective treatment for Zika virus is discovered, healthcare providers must be AVP (aware, vigilant and proactive) in order to lessen the spread and impact of the implicated devastating birth defects (microcephaly) and other neurological disorders (eg Guillain‐Barré Syndrome) of this infection. Unfortunately, many knowledge gaps exist. There is an urgent need for a reliable, inexpensive diagnostic test, an effective treatment and an approved and readily available vaccine. Zika is a single-stranded ribonucleic acid (RNA) flavivirus transmit- The Zika virus poses a huge public health threat. For example, in the United States, 11, 12 where the most vulnerable to the mosquito-borne illness will likely be Gulf Coast states such as Florida and Texas, the White House asked for extensive funding to fight the Zika virus. 13 The Zika virus belongs to the family Flaviviridae and genus Flavivirus. Flaviviruses are a type of arbovirus, a large group encompassing RNA-viruses which often rely on arthropod vectors such as mosquitoes or ticks for transmission. Other arboviruses include dengue, yellow fever, West Nile virus, Japanese encephalitis virus and chikungunya. The Zika virus is enveloped and icosahedral (consisting of identical subunits that make up equilateral triangles arranged symmetrically) with a non-segmented, single-stranded, positivesense RNA genome which can directly translate into viral proteins. Transmission of the Zika virus can occur by the bite of an infected female Aedes aegypti mosquito. 7 (Figure 1 ) Historically, the Aedes aegypti mosquito was the vector for the transmission of yellow fever, which is much less of a threat today owing to effective vaccines. 15 In the case of Zika, the virus replicates in the mosquito's epithelial cells and then its salivary glands. About five to 10 days after it infects a mosquito, the Zika virus is detectable in that mosquito's saliva and can be transmitted to humans. If the mosquito's saliva can be inoculated into human skin, the virus infects epidermal keratinocytes, skin fibroblasts and the Langerhans cells. The pathogenesis of the Zika virus in humans remains to be elucidated, but it is thought to spread next to the lymph nodes and then into systemic circulation. 16 It is not clear if and how other means of transmission can occur, but it appears that the virus can be transferred by mother to foetus, by sexual contact with an infected man, and by blood transfusion. [17] [18] [19] When humans encroach on the natural habitat of other species, the result is either extinction of the invaded species or commensalism, that is, the invaded species continues to breed in a human-dominated environment. In the case of the Aedes aegypti mosquito, which requires a vertebrate source of blood, the mosquito develops a preference for the most readily available source of that blood, namely humans. 15, 20 Humans occupy the largest range of terrestrial habitations and when a species, such as Aedes aegypti evolves abilities to survive together with humans, their territories may expand with human mobility. 15 Deceptively, the majority of people infected with Zika virus will not develop serious clinical symptoms. 3, 21, 22 The incubation period is currently thought to be about three to 12 days, and the illness itself lasts about 2-7 days. 23 The main symptoms are an eruptive skin rash (exanthema) (90% of patients), arthralgia (65%), nonpurulent conjunctivitis (55%) and headache. 3 The exanthem may be morbilliform or be comprised of tiny papules, and it tends to descend, that is, start on the upper portion of the body and move down as the illness progresses. 24 If fever is present, it is low. Diffuse symptoms, such as retro-orbital pain, abdominal pain, nausea, vomiting, There are a few case reports in the literature describing the presentation of Zika infection. A male patient returning from a vacation in Puerto Rico experienced headache and lethargy, and the next day noticed erythematous eruptions on his hands and arms. 24 Within 24 h, the eruptions became more prominent and spread to his trunk but he never experienced pruritus. His eyes were red, and on the third day he had skin eruptions on his knees and feet along with burning pain in his feet. Joint pain of the wrists, knees and ankles was noted on the fourth day, and these symptoms continued until they resolved spontaneously on the eighth day. He did not have fever, cough, sore throat or any gastrointestinal symptoms. Tiny pink and red erythematous papules were noted on his head, neck, trunk and extremities along with petechiae on the hard palate. Lymph nodes were not palpable. In a study of pregnant women infected by the Zika virus reported as a case series in Brazil, the most frequently reported symptoms were rash (72%), fever (45%), arthralgia (38%), headache (17%) and pruritus (14%). 25 However, this is a case series and these statistical findings cannot be extended to all populations. Zika virus infection can result in a clinical syndrome that produces no symptoms, diffuse symptoms or symptoms similar to those of dengue or chikungunya viruses. For that reason, diagnoses must rely on more than clinical criteria. 9 The presence of the above-described symptoms (rash, low fever, joint pain and headache) should be considered, as well as historical factors, such as recent travel to an affected area. 22 Other similar diseases, such as malaria, chikungunya and dengue fever should be ruled out. The Zika virus can be definitively diagnosed by RT-PCR tests on the blood or other body fluids (urine, saliva), a test that is rapid to administer, highly specific, 26 week of the illness. The best results are obtained when the test is administered early in the acute phase of the illness. Serum antibody testing may be challenged by cross-reactivity with other arboviruses, such as dengue. 27 The US Food and Drug Administration (FDA) has authorized the emergency use of RT-PCR kits to be used to detect the Zika virus in the blood. 28 Diagnoses based on molecular biology may result in a high rate of false-negatives because the Zika virus genome is made of RNA which is extremely fragile. It is possible, but in many cases cost prohibitive, to isolate the Zika virus in cell cultures such as Vero cells and identify them by indirect immunofluorescence. 29 Urine testing may be more reliable for Zika virus infections than blood tests. For example, the Florida Department of Health, Bureau of Public Health Laboratories, tested specimens from 913 persons who met criteria for Zika virus testing and of these, 91 had confirmed or probable Zika virus infection; all cases were related to travel. Investigators then tested the Zika patients using different test modalities on different days to assess the most sensitive, specific F I G U R E 1 The femaleAedes aegyptimosquito (left), active in the daylight hours, is the vector for the Zika virus (right). Images purchased from iStock and efficient testing algorithm. Over 90% of those with an RT-PCR confirmed Zika diagnosis tested positive with urine tests but results were much lower with blood and saliva testing. 30 New point-ofcare diagnostic assays are being developed for commercialization. 31 Ideally, these tests should be easy to administer, cost-effective and provide highly specific and highly sensitive test results. At present, there are no vaccines and no antiviral agents to treat the Zika virus. 32 Zika infection is usually relatively mild, self-limiting and rarely fatal. Symptoms may persist for a few days to a week. Many Zika virus can induce autophagy in infected neural cells. Murine studies suggest that the virus may increase apoptosis, improper neural stem cell orientation and premature neuronal differentiation, and decrease progenitor cells, which, in turn, reduces grey matter and thus brain size and thereby leads to microcephaly ( Figure 2 ). 34, 35 Microcephaly, a birth defect associated with abnormal brain development and manifesting as a head of small circumference, is associated with neurological problems such as hypertonia, spasticity, hyperreflexia and seizures. 36 The Zika virus has been found in foetal brain tissue. 8 The first association between the virus and microcephaly was reported in Brazil in 2015. 37 More recent studies indicate significant cellular death of neural stem cells infected by the Zika virus, which supports the hypothesis that the Zika virus inhibits foetal brain development. 38 [42] [43] [44] Using embryonic stem-cell-derived cerebral organoids to recapitulate first trimester foetal brain development, it was shown that • Risk assessment is difficult with the Zika virus, in that it is not known how many people in an epidemic region will be infected and of those infected, how many will be symptomatic and/or how many will be pregnant women. It is not known how many pregnant women infected with the Zika virus will pass the infection along to the foetus and it is further unknown how many Zika-infected newborns will exhibit neurodevelopmental abnormalities. It is also unclear if Zika infection at a particular gestational age is more, or less, dangerous to the foetus than infection at other times. Thus, providers and public health experts may be underestimating or overestimating the public health threat. In theory, the Zika virus can be transmitted wherever the mosquito vector exists. For example, in the United States, this encompasses a large area for seasonal transmission and a smaller area, around the Gulf Coast, for year-round transmission. 59 The Zika outbreaks thus far have placed great burdens on local populations that were unprepared to meet the threat. Urgently needed in such situations are reliable diagnostic methods (which is complicated by cross-reactivity with other types of flaviviruses, such as dengue), initiatives to limit the mosquito vectors, public health awareness campaigns to increase prevention, a comprehensive action plan that consists of health promotion, reproductive health recommendations for antenatal control and epidemiological surveillance. 5 Since Zika cannot be treated once it starts and since there are currently no vaccines to prevent infection, the best methods at our disposal involve aggressive prevention. This would include mosquito control, public awareness campaigns, limiting travel by pregnant women to locations where Zika is particularly prevalent and clinician education. Aggressive educational campaigns targeting pregnant women and women who could become pregnant are needed. Aedes mosquitoes 37 are present in many tropical and subtropical regions and are expanding their territory into more subtropical regions. 60 Aedes aegypti is known to transmit the Zika virus, and Aedes albopictus could possibly be a vector as well. 61, 62 The Zika virus is a nationally notifiable condition in the United States, and clinicians should be aware that they need to report confirmed and even suspected cases of Zika viral infection to the state or local health departments. 9 Sexual transmission of the Zika virus (from infected male to female) has been described in the US and other countries but is thought to be rare 65 and its epidemiological importance unclear. 66 It is not known if men with asymptomatic Zika infection can transmit the virus through sexual contact. 67 Testing asymptomatic men is not recommended as it is unclear at present whether positive blood test results mean the virus is present in semen and, conversely, whether negative blood test results mean it is not. 67 Clinicians should educate all women of childbearing potential, particularly those in vector-rich areas, about the risk contracting the Zika virus and ways to protect themselves. 67 This education should include basic facts about the infection, common symptoms of infection and ways to protect against mosquito bites. Women of childbearing age who may have been exposed to the Zika virus and have had symptoms (such as fever, rash, arthralgia or conjunctivitis) should have a blood test for Zika infection. 67 Women with diagnosed or suspected Zika infection who are not pregnant should wait at least 8 weeks after the onset of symptoms before attempting to conceive a child; men should wait at least 6 months. 67 The Zika infection may be asymptomatic or result in only mild or vague symptoms that are overlooked. Thus, women may have been It is not known if the Zika virus causes miscarriage. 70, 71 In a study of 88 pregnant women with rash, women infected with the Zika virus had significantly more adverse pregnancy outcomes (up to and including foetal death) than those without Zika infection (29% vs. 0). 72 In a small case series (n = 9), Zika virus infection was more likely to be associated with adverse pregnancy outcomes when it occurred in the first trimester versus later in the course of the pregnancy. 73 Healthcare professionals who work in obstetrics must take special precautions to avoid infection with Zika, which may be present in body fluids, including blood and amniotic fluid. During routine, uncomplicated delivery, a pregnant woman may lose 500 ml of blood and a greater volume than that of amniotic fluid. Gloves and a surgical mask should be worn if a catheter is placed or a needle is inserted for epidural injection. 74 These precautions should be observed routinely, even if the patient is not diagnosed with or suspected to have a Zika infection, since the infection may be asymptomatic. All healthcare workers associated with labour and delivery should use standard precautions, including gloves, a mask, eye protection and an impermeable gown. Zika viral RNA can be detected in breast milk, but there is no evidence that the virus can be transmitted in this way. 17 Although there is no documented case of Zika virus transmission through fertility treatments (such as donated embryos or gametes), it seems medically possible that this could occur, in that it is unlikely the cryopreservation process would destroy the Zika virus. The FDA has recommended that anonymous donors to fertility clinics be declared ineligible if in the last 6 months they have been diagnosed with the Zika virus, have lived or travelled to an area with active Zika virus transmission or have had sex with a male partner who has been diagnosed with the Zika virus or travelled to an area of active Zika virus transmission. 67 Directed donors must meet the same eligibility criteria as anonymous donors, but these recommendations would not apply to sexually intimate couples. Although work is ongoing for a vaccine against Zika, none is currently available. 2, 32 Furthermore, vaccines need to be inexpensive in order to assure proper distribution in epidemic-plagued areas, which may not be well-developed economically. Control of vectors can help reduce the spread of these viruses but also requires considerable resources. These might include biological control of mosquito larvae, the use of Wolbachia-infected or transgenic mosquitoes, and traditional methods to avoid mosquito bites (netting, insecticides). Mosquito control can be further improved by changes in urban sanitation, water supply and housing to reduce the opportunities for them to breed. Promising results have been reported by the CDC, which have developed an autocidal gravid ovitrap (AGO) to attract and capture Aedes ageypti mosquitoes. For example, in Puerto Rican communities where the AGO traps were deployed, the incidence of chikungunya virus infection was reduced. 75 As the AGO traps are simple, inexpensive and low-maintenance devices that require no pesticides, these may represent an important and economically viable weapon in the fight against the Zika virus and other mosquitoborne diseases. Reliable, cost-effective test measures are urgently needed to better define and thus monitor the Zika-infected population. In vitro testing has demonstrated that the viral polymerase inhibitor 7-Deaza-2′-C-methyladenosine (7DMA) inhibits Zika virus replication. 60 When IFN-α/β and IFN-γ knockout AG129 mice were infected with the Zika virus, they developed acute neutrophilic encephalitis with an accumulation of viral antigens in brain and spinal cord neurons. High levels of viral RNA were found in the spleen, liver and kidney of these mice and there was a systematic increase in the serum levels of IFN-γ and IL-18 in infected mice. The virus was also detected in mice testicles. 7DMA was also shown to reduce viremia and delayed virus-induced morbidity and mortality in infected mice. Future work may involve repurposing the seasonal influenza vaccine for prevention of Zika virus infection. 76 A potential target for therapeutic antibodies against the Zika virus may be an E protein fusion loop epitope. The flavivirus has an envelope (E) glycoprotein that is responsible for virus entry and represents a good target for neutralizing antibodies for other flaviviruses. 77 The crystal structure of the Zika virus helicase may be a target for drug development. 78 Clinicians on the frontline of health care must take a proactive role in talking to their patients about the Zika virus, the potential risks of infection, and associated symptoms. Women of childbearing potential in particular should be educated about Zika and its symptoms, told about its risks and provided with instructions on how to reduce the risk of mosquito bites. These patients should be advised to wear protective clothing and use mosquito repellent when going outdoors. Large international and national agencies need to mobilize forces to combat the Zika virus. Local authorities should begin initiatives to reduce mosquitoes in their localities, either through spraying and other ongoing efforts, or through public awareness campaigns that ask local citizens to be aware of potential mosquito breeding grounds (areas where water pools or collects) and to drain them. Healthcare providers should keep abreast of the latest developments in Zika virus diagnosis and treatment. Pregnant women who are suspected of being infected with the Zika virus should be promptly referred to specialists. As much as possible, clinicians should share knowledge with each other about outbreaks, symptoms and specific cases. The Zika virus is an under-the-radar epidemic and one that may challenge our abilities to work in multinational, multidisciplinary teams. Work is advancing rapidly to better understand, diagnose and treat the Zika virus. The FDA, CDC, the World Health Organization (WHO) and other agencies around the world are taking proactive and aggressive steps to contain the Zika virus. Healthcare providers should educate patients on the risks of the Zika virus and how to prevent it. Further study, better diagnostic tools, more treatment options and vaccinations are urgently needed. None declared. https://orcid.org/0000-0001-5658-1471 Robert B. Raffa https://orcid.org/0000-0002-1456-4451 Zika virus-associated Guillain-Barre syndrome variant in Haiti Zika virus pandemic: a human and public health crisis Zika virus outbreak on Yap Island, Federated States of Micronesia Rapid spread of Zika virus in the Americas -implications for public health preparedness for mass gatherings at the 2016 Brazil Olympic Games Clinical and epidemiological characterization of laboratory-confirmed autochthonous cases of Zika virus disease in Mexico Epidemiology Update Zika virus spreads to new areas -region of the Americas Zika virus associated with microcephaly Zika virus in the Americas: an obscure arbovirus comes calling Entry routes for Zika virus in Brazil after 2014 world cup: new possibilities Zika virus in the Americas: early epidemiological and genetic findings Senate approves $1.1 billion to fight Zika virus. USA Today Our Response to the Zika Virus History of domestication and spread of Aedes aegypti-a review The reemergence of Zika virus: a review of pathogenesis, clinical manifestations, diagnosis and treatment Euro Surveillance: Bull Eur sur les maladies transmissibles = Potential sexual transmission of Zika virus Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia Evolution of mosquito preference for humans linked to an odorant receptor Update on Zika virus infection in pregnancy Zika virus: what do emergency physicians need to know? Zika virus: an emerging infectious threat Mucocutaneous findings and course in an adult with Zika virus infection Ocular findings in infants with microcephaly associated with presumed Zika virus congenital infection in Salvador, Brazil Interim guidance for Zika virus testing of urine -United States Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia Virus Response Updates from FDA. FDA. Emergency Preparedness and Response Web site Zika virus infection, Cambodia Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travel-associated Zika virus disease -Florida Rapid, low-cost detection of Zika virus using programmable biomolecular components Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development Update: interim guidelines for health care providers caring for pregnant women and women of reproductive age with possible Zika virus exposure -United States An overview of the current medical literature on Zika virus Zika and microcephaly: causation, correlation, or coincidence? Microbes Infect Possible association between Zika virus infection and microcephaly-Brazil An emerging cause of concern in Europe: Zika virus, the developing CNS and the pediatric neurologist Zika virus infects human cortical neural progenitors and attenuates their growth Ministerio da Saude investiga 4.293 casos de microcefalia no pais. Brazilian Ministry of Health Zika virus infection and pregnancy CDC guidelines for pregnant women during the Zika virus outbreak Zika virus: a roar after years of whispering Available evidence of association between Zika virus and microcephaly Association between Zika virus infection and microcephaly in Brazil Congenital Zika virus infection: a review with emphasis on the spectrum of brain abnormalities Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3 Zika virus impairs growth in human neurospheres and brain organoids Zika; a continuous global threat to public health Epidemiology of Guillain-Barre syndrome Zika virus infection complicated by Guillain-Barre syndrome-case report Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study The mysterious Zika virus: adding to the tropical flavivirus mayhem Zika virus and the blood supply: what do we know Survey of blood collection centers and implementation of guidance for prevention of transfusion-transmitted Zika virus infection -Puerto Rico Restriction of Zika virus by host innate immunity Complete genome sequences of five Zika virus isolates Complete genome sequences of Zika virus strains isolated from the blood of patients in Thailand in 2014 and the Philippines in 2012 Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas Anticipating the international spread of Zika virus from Brazil The viral polymerase inhibitor 7-Deaza-2'-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model Zika virus: new clinical syndromes and its emergence in the western hemisphere Differential susceptibilities of Aedes aegypti and Aedes albopictus from the Americas to Zika virus Zika virus: new emergencies, potential for severe complications, and prevention of transfusion-transmitted Zika fever in the context of co-circulation of arboviruses Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission -continental United States Zika virus and microcephaly -more questions than answers? CDC updates interim guidance on caring for women with possible exposure to Zika virus Zika virus in Brazil and macular atrophy in a child with microcephaly Interim guidelines for the evaluation and testing of infants with possible congenital Zika virus infection -United States Interim guidelines for pregnant women during a Zika virus outbreak -United States Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses -Brazil Zika virus infection in pregnant women in Rio de Janeiro -preliminary report Zika virus infection among U.S. pregnant travelers Protecting health workers from Zika during labor and delivery Reduced incidence of chikungunya virus infection in communities with ongoing Aedes aegypti mosquito trap intervention studies -Salinas and Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody The crystal structure of Zika virus helicase: basis for antiviral drug design Congenital Zika syndrome The Zika virus: Lurking behind the COVID-19 pandemic?